Physician profile
Steve Watson
NPI 1265699649
$7,836.81
in general payments reported to CMS, 2019-2025
23 companies · $3,059 in 2025
The $3,059 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2023: $1,288 · 2024: $3,322 · 2025: $3,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,159 · Education: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,159.23 |
| Education | $509.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.13 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $1,247.21 | 2023-2025 | Levulan Kerastick, Ilumya, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $1,018.88 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $985.07 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $480.67 | 2023-2025 | Sotyktu |
| Amgen INC. | $468.34 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $367.95 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $346.19 | 2024-2025 | |
| Ucb, INC. | $287.22 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $232.81 | 2023-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $213.25 | 2023-2025 | Tremfya, Stelara, Simponi |
| Arcutis Biotherapeutics, INC. | $177.80 | 2024-2025 | Zoryve |
| Ge Healthcare | $168.00 | 2021 | |
| Incyte Corporation | $165.36 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $111.52 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $83.14 | 2024-2025 | Nemluvio |
| Organon LLC | $41.74 | 2025 | Vtama |
| Biofrontera INC. | $38.85 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Strata Skin Sciences, INC. | $35.79 | 2024 | Xtrac |
| Genentech USA, INC. | $23.09 | 2024 | Erivedge |
| Kyowa Kirin, INC. | $22.66 | 2025 | |
| Lnhc, INC | $20.91 | 2025 | Zelsuvmi |
| Botanix Sb INC | $18.23 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.